AnGes has signed an agreement for regulatory approval, commercialisation and supply of Eiger Biopharmaceuticals’ Zokinvy (lonafarnib) to treat Hutchinson-Gilford progeria syndrome (HGPS or progeria) and processing-deficient progeroid laminopathies (PL) in Japan.
TORONTO--(BUSINESS WIRE)--Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases associated with vascular dysfunction, announced today it has dosed the first patient in the Phase 2a clinical study to evaluate AV-001 in patients hospitalized with severe COVID-19 disease. AV-001 is a novel pegylated peptide targeting the Tie2 receptor designed to activate the angiopoietin/Tie2 signaling pathway to normalize the vasculature.
NEW YORK, Aug. 24, 2021 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 effective prior to the opening of trading on Monday, August 30:
With two approvals for its cancer drug Tazverik and trials in various other tumor types underway, Epizyme is making changes at the top. CEO Robert Bazemore is handing the reins to Grant Bogle, a biopharma veteran who’s been on the company’s board since 2019.
Francis Crick institute and university of Dundee have screened thousands of drug and chemical molecules and identified a range of potential antivirals that could be developed into new treatments for COVID-19 or in preparation for future coronavirus outbreaks. Scientists identified 15 molecules that inhibit the growth of SARS-COV-2 by blocking different enzymes involved in its replication. The tests were based on fluorescent changes with a special imaging tool detecting if enzymes has been affected, they then validated accordingly. While COVID-19 vaccines are being rolled out, there are still few drug options that can be used to treat patients with the virus, reduce symptoms and speed up recovery time. These treatments are especially important for groups where the vaccines are less effective, such as some patients with blood cancer. The 15 molecules were also tested in combination with remdesivir, an antiviral being used to treat patients with COVID-19.
Dr. Joshua Liao explores what motivates human behavior, and how to make vaccine behavior changes that last for the long term.
On 30 June 2021 Marina Serpova, a chairperson of Management Board of Latvijas Aptieka Ltd., ended her duties at Management Board of Latvijas Aptieka Ltd.
Copenhagen, DK and Boston, MA, June 30, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.
The new Code has been updated to reflect changes in the pharma environment
CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced results from the company’s Phase 2b trial, ReDUX4, in people with facioscapulohumeral muscular dystrophy (FSHD). Results being presented with losmapimod at the FSHD International Research Congress today showed clinically relevant and statistically significant* benefits versus placebo on multiple measures of structural and functional FSHD disease progression and patient reported outcomes at 48 weeks. Losmapimod was generally well-tolerated, with no drug-related serious adverse events reported. Consistent with the previously reported interim analyses the primary endpoint was not met. Changes in DUX4-driven gene expression, which were included in the trial as an experimental biomarker endpoint, could not be demonstrated, the Company believes due to several technical and biologic variables with the endpoint. Based on today’s results, the Company plans to meet with health authorities, including the U.S. Food and Drug Administration (FDA), in the second half of 2021 to determine the regulatory path for losmapimod in FSHD.